在两种疟疾共流行区减少恶性疟感染后间日疟风险——一项随机对照试验(PRIMA)
PRIMA 是一项在孟加拉国、印度尼西亚和埃塞俄比亚开展的多中心、基于医疗卫生机构、随机、对照、开放标签试验,纳入无并发症恶性疟、G6PD 活性≥70% 调整男性中位数且血红蛋白≥8g/dl 的患者,按 1:1 随机接受标准杀裂殖体治疗加 7 天高剂量伯氨喹(总剂量 7mg/kg)或标准治疗,随访至第 63 天。主要终点为第 63 天任何间日疟寄生虫血症的发生风险。该研究评估在两种疟疾共流行地区对间日疟和恶性疟均采用普遍根治性治疗的潜在获益。
要点
- 在恶性疟与间日疟共流行区,恶性疟后间日疟寄生虫血症风险升高。
- PRIMA 试验将无并发症恶性疟患者按 1:1 随机接受标准治疗加 7 天高剂量伯氨喹(总剂量 7mg/kg)或标准治疗。
- 主要终点为第 63 天任何间日疟寄生虫血症的发生风险。
核心结论
- 该研究评估在两种疟疾共流行地区对间日疟和恶性疟均采用普遍根治性治疗的潜在获益;若被发现安全有效,普遍根治性治疗可能代表一种具有成本效益的方法,以清除未被识别的间日疟感染并加速间日疟消除。
研究设计与样本
- 多中心、基于医疗卫生机构、随机、对照、开放标签试验,在孟加拉国、印度尼西亚和埃塞俄比亚开展。
- 纳入无并发症恶性疟、G6PD 活性≥70% 调整男性中位数(AMM)且血红蛋白≥8g/dl 的患者,按 1:1 随机接受标准杀裂殖体治疗加 7 天高剂量伯氨喹(总剂量 7mg/kg)或标准治疗。
- 患者每周随访至第 63 天。
主要发现
- 主要终点为第 63 天任何间日疟寄生虫血症的发生风险。
- 次要终点包括第 63 天症状性间日疟的发生风险及任何恶性疟寄生虫血症的风险。
- 次要安全性结局包括不良事件和严重不良事件的比例、严重贫血(Hb<5g/dl 和 <7g/dl)和/或需要输血的发生风险、血红蛋白下降≥25% 伴或不伴血红蛋白尿的发生风险、以及血红蛋白下降≥25% 至 7g/dl 以下伴或不伴血红蛋白尿的发生风险。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Plasmodium vivax forms dormant liver stages that can reactivate weeks or months following an acute infection. Recurrent infections are often associated with a febrile illness and can cause a cumulative risk of severe anaemia, direct and indirect mortality, and onward transmission of the parasite. There is an increased risk of P. vivax parasitaemia following falciparum malaria suggesting a rationale for universal use of radically curative treatment in patients with P. falciparum malaria even in the absence of detectable P. vivax parasitaemia in areas that are co-endemic for both species. METHODS: This is a multicentre, health care facility-based, randomized, controlled, open-label trial in Bangladesh, Indonesia and Ethiopia. Patients with uncomplicated falciparum malaria, G6PD activity of ≥70% of the adjusted male median (AMM) and haemoglobin levels ≥8g/dl are recruited into the study and randomized to either receive standard schizonticidal treatment plus 7-day high dose primaquine (total dose 7mg/kg) or standard care in a 1:1 ratio. Patients are followed up weekly until day 63. The primary endpoint is the incidence risk of any P. vivax parasitemia on day 63. Secondary endpoints include incidence risk on day 63 of symptomatic P. vivax malaria and the risk of any P. falciparum parasitaemia. Secondary safety outcomes include the proportion of adverse events and serious adverse events, the incidence risk of severe anaemia (Hb<5g/dl and <7g/dl) and/or the risk for blood transfusion, the incidence risk of ≥ 25% fall in haemoglobin with and without haemoglobinuria, and the incidence risk of ≥ 25% fall in haemoglobin to under 7g/dl with and without haemoglobinuria. DISCUSSION: This study evaluates the potential benefit of a universal radical cure for both P. vivax and P. falciparum in different endemic locations. If found safe and effective universal radical cure could represent a cost-effective approach to clear otherwise unrecognised P. vivax infections and hence accelerate P. vivax elimination. TRIAL REGISTRATION: NCT03916003 . Registered on 12 April 2019.
引用
- Thriemer K, Degaga TS, Christian M, et al. Reducing the risk of Plasmodium vivax after falciparum infections in co-endemic areas-a randomized controlled trial (PRIMA). Trials. 2022. PMID: 35585641. doi:10.1186/s13063-022-06364-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。